Background
==========

In healthy volunteers, we sought to determine the safety, tolerability, and immunogenicity of ADVAX, a subtype B\'/C, DNA-based, multigenic, HIV-1 vaccine candidate, when injected intramuscularly immediately followed by *in vivo*electroporation (EP) using the TriGrid™ Delivery System.

Methods
=======

Forty healthy volunteers aged 18--60 were enrolled in a double blind randomized phase-I trial. Eight volunteers each received either low dose (LD, 0.2 mg); mid dose (MD, 1.0 mg); or high dose (HD, 4.0 mg) ADVAX or saline placebo via EP. Another eight volunteers received 4.0 mg ADVAX intramuscularly (IM). Vaccinations were given at weeks 0 and 8. The protocol was subsequently amended to administer a third dose of HD EP/placebo at week 36 to volunteers receiving either HD ADVAX via EP (n = 8) or placebo via EP (n = 3). Total study follow-up is 14 months.

Results
=======

There have been no vaccine or device related serious adverse events to date. After two vaccinations in all subjects, the IFNg ELISPOT response rates were IM: 1/8 (13%), LD-EP: 3/8 (38%) MD-EP: 7/8 (88%) and HD-EP: 6/8 (75%). In the same order, the mean (range) response to peptide pools spanning all antigens was 72, 120 (70--193), 151 (53--440), and 141 (59--336) SFC/million PBMCs. The breadth of the response improved with EP and increasing dosage, with responses to 1, 1, 3, and 4 of the 4 ADVAX gene products. ICCS analysis of ELISPOT responders revealed a balanced CD4+/CD8+ response. There were no responses to placebo, by definition. An analysis of responses after the third vaccination in the high dosage group is ongoing.

Conclusion
==========

This study is the first demonstration in healthy volunteers that EP *in vivo*is safe, tolerable, and effective in improving the magnitude and breadth of cellular immune responses to a DNA-based vaccine.
